Akèy › Kansè san › North Carolina › Durham
Etid klinik pou Kansè san nan Durham, NC
16 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Ap rekriteFaz 3
- Duke Cancer Center ( Site 0028), Durham
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill · 10 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Durham VA Medical Center, Durham
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 27, Chapel Hill · 10 mi lwen
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Duke University, Durham
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Ap rekriteEtid obsèvasyon
- Duke University Medical Center, Durham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi lwen
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10 mi lwen
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Ap rekrite
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Ap rekriteFaz 2
- Lineberger Cancer, Chapel Hill · 10 mi lwen
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
Ap rekrite
- 2400 Pratt Street, Durham
Implementation of an Oral Chemotherapy Adherence Intervention
Ap rekrite
- UNC Chapel Hill, Chapel Hill · 10 mi lwen
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Duke Blood Cancer Center, Durham
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Ap rekriteFaz 1 bonè
- Duke University Health System, Durham
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- New York City, NY26 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Baltimore, MD18 etid
- Seattle, WA18 etid
- Los Angeles, CA17 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Atlanta, GA13 etid
- Nashville, TN13 etid
- Edison, NJ13 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.